Acute lymphatic leukemia (ALL) is the most common cancer in children under the age of 14 years. With optimum treatment, approximately 75 percent of children are currently cured, but the treatment consists of severe chemotherapy with many side effects. Researchers have identified new genetic mutations that lead to T-ALL, a variant of ALL. They have unmasked the ribosome — the molecular machine in the cell that is involved in the production of proteins — as a weak spot in leukemia cells. Their research has also shown that there is a difference in T-ALL between adults and children. Both findings can be important in the search for improved treatments for T-ALL.